| Musaddiq Waheed, MD | |
|
252 S 4th St Fl 3, Lebanon, PA 17042-6111 | |
| (717) 270-4876 | |
| (717) 270-3875 |
| Full Name | Musaddiq Waheed |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 252 S 4th St Fl 3, Lebanon, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861695157 | NPI | - | NPPES |
| 376907502A | Medicaid | GA | |
| P00694574 | Other | GA | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD470015 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hca Houston Healthcare Pearland | Pearland, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hospital Medicine Services Of Tx, Pc | 3274998067 | 212 |
News Archive
Prodromal psychiatric symptoms may be more common in patients with Huntington's disease than previously thought and worsen as the condition progresses, longitudinal study findings show.
Remon Medical Technologies a privately held medical device company, today announced that it has raised $16 million in the initial close of a Series C financing.
Personalized cancer treatment is one step closer to becoming a reality for more patients, thanks to a Cancer Council Beat Cancer Project grant awarded to the University of South Australia researcher Dr. Stephanie Reuter Lange to explore how computer-based modeling can optimize cancer treatment and remove the need for expensive clinical trials.
The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.
The discovery of a new compound by Michigan State University researchers could lead to improved chemotherapy treatments for different types of cancers – potentially with fewer side effects.
› Verified 9 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629307095 PECOS PAC ID: 3476688318 Enrollment ID: O20100317001021 |
News Archive
Prodromal psychiatric symptoms may be more common in patients with Huntington's disease than previously thought and worsen as the condition progresses, longitudinal study findings show.
Remon Medical Technologies a privately held medical device company, today announced that it has raised $16 million in the initial close of a Series C financing.
Personalized cancer treatment is one step closer to becoming a reality for more patients, thanks to a Cancer Council Beat Cancer Project grant awarded to the University of South Australia researcher Dr. Stephanie Reuter Lange to explore how computer-based modeling can optimize cancer treatment and remove the need for expensive clinical trials.
The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.
The discovery of a new compound by Michigan State University researchers could lead to improved chemotherapy treatments for different types of cancers – potentially with fewer side effects.
› Verified 9 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas-tcg Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902384464 PECOS PAC ID: 3678825312 Enrollment ID: O20181009000584 |
News Archive
Prodromal psychiatric symptoms may be more common in patients with Huntington's disease than previously thought and worsen as the condition progresses, longitudinal study findings show.
Remon Medical Technologies a privately held medical device company, today announced that it has raised $16 million in the initial close of a Series C financing.
Personalized cancer treatment is one step closer to becoming a reality for more patients, thanks to a Cancer Council Beat Cancer Project grant awarded to the University of South Australia researcher Dr. Stephanie Reuter Lange to explore how computer-based modeling can optimize cancer treatment and remove the need for expensive clinical trials.
The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.
The discovery of a new compound by Michigan State University researchers could lead to improved chemotherapy treatments for different types of cancers – potentially with fewer side effects.
› Verified 9 days ago
| Entity Name | T & Z Hospital Solutions Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467154518 PECOS PAC ID: 0244695468 Enrollment ID: O20230422000277 |
News Archive
Prodromal psychiatric symptoms may be more common in patients with Huntington's disease than previously thought and worsen as the condition progresses, longitudinal study findings show.
Remon Medical Technologies a privately held medical device company, today announced that it has raised $16 million in the initial close of a Series C financing.
Personalized cancer treatment is one step closer to becoming a reality for more patients, thanks to a Cancer Council Beat Cancer Project grant awarded to the University of South Australia researcher Dr. Stephanie Reuter Lange to explore how computer-based modeling can optimize cancer treatment and remove the need for expensive clinical trials.
The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.
The discovery of a new compound by Michigan State University researchers could lead to improved chemotherapy treatments for different types of cancers – potentially with fewer side effects.
› Verified 9 days ago
| Entity Name | Hospital Medicine Services Of Tx, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881392363 PECOS PAC ID: 3274998067 Enrollment ID: O20230501001255 |
News Archive
Prodromal psychiatric symptoms may be more common in patients with Huntington's disease than previously thought and worsen as the condition progresses, longitudinal study findings show.
Remon Medical Technologies a privately held medical device company, today announced that it has raised $16 million in the initial close of a Series C financing.
Personalized cancer treatment is one step closer to becoming a reality for more patients, thanks to a Cancer Council Beat Cancer Project grant awarded to the University of South Australia researcher Dr. Stephanie Reuter Lange to explore how computer-based modeling can optimize cancer treatment and remove the need for expensive clinical trials.
The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.
The discovery of a new compound by Michigan State University researchers could lead to improved chemotherapy treatments for different types of cancers – potentially with fewer side effects.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Musaddiq Waheed, MD 3421 Concord Rd, York, PA 17402-9001 Ph: (717) 270-4876 | Musaddiq Waheed, MD 252 S 4th St Fl 3, Lebanon, PA 17042-6111 Ph: (717) 270-4876 |
News Archive
Prodromal psychiatric symptoms may be more common in patients with Huntington's disease than previously thought and worsen as the condition progresses, longitudinal study findings show.
Remon Medical Technologies a privately held medical device company, today announced that it has raised $16 million in the initial close of a Series C financing.
Personalized cancer treatment is one step closer to becoming a reality for more patients, thanks to a Cancer Council Beat Cancer Project grant awarded to the University of South Australia researcher Dr. Stephanie Reuter Lange to explore how computer-based modeling can optimize cancer treatment and remove the need for expensive clinical trials.
The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.
The discovery of a new compound by Michigan State University researchers could lead to improved chemotherapy treatments for different types of cancers – potentially with fewer side effects.
› Verified 9 days ago
Dr. Gabrielle Frenkel, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 30 N 4th St, Lebanon, PA 17046 Phone: 717-274-0474 | |
Mrs. Heather Heck, CRNP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1701 Cornwal Road, Lebanon, PA 17042 Phone: 717-675-1780 | |
Anthony Lal, Family Medicine Medicare: Medicare Enrolled Practice Location: 30 N 4th St, Lebanon, PA 17046 Phone: 717-274-0474 | |
Ilham Ahmed Umar, Family Medicine Medicare: Medicare Enrolled Practice Location: 30 N 4th St, Lebanon, PA 17046 Phone: 717-274-0474 | |
Robert Greville Brummett, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 855 Tuck St, Suite 1, Lebanon, PA 17042 Phone: 717-273-5395 | |
Wray Anthony Gerard, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4th & Walnut St, Good Samaritan Hospital, Lebanon, PA 17042 Phone: 717-270-7740 Fax: 717-270-3877 | |
Dr. James D Stauffer, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1700 S Lincoln Ave, Lebanon, PA 17042 Phone: 717-272-6621 Fax: 717-228-6002 |